LGMC Conducting Registry Study on Overactive Bladder


Lafayette General Medical Center is seeking men and women, ages 18 and older, diagnosed with overactive bladder (OAB) and initiating a new course of treatment with mirabegron or an antimuscarinic medication for OAB to participate in a prospective, non-interventional registry study as part of a clinical trial.

This registry study will identify factors associated with improved effectiveness in pharmacologic therapy of overactive bladder based on patient perspectives measured by responses to a questionnaire.

Internal Medicine physician Bradley J. Chastant II, M.D., is principle investigator of this study, sponsored by Astellas Scientific and Medical Affairs.

Lafayette General Health (LGH) participates in clinical trials and studies to help improve patient care and disease prevention. Clinical trials can offer several benefits, such as access to investigational treatments and drugs that might not otherwise be available. Trials also help expand knowledge about the best ways to treat disease.

When patients participate in a clinical trial, they are not only advancing medical technology, they are providing a valuable benefit to future generations. The goal of LGH clinical trials is to support the patient-centered approach to health care.

For more information on this and other clinical trials available at Lafayette General Medical Center, call (337) 289-8658 or visit LafayetteGeneral.com/ClinicalTrials.

Back to News Listing